Genfit, a Phase 3 French biotech developing therapies for NASH, raised $135 million by offering 6.65 million ADSs at $20.32 per ADS. It had previously filed to raise $132 million by offering 5.0 million ADSs at $26.33. Genfit plans to list on the Nasdaq under the symbol GNFT. SVB Leerink and Barclays acted as lead managers on the deal.
